A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults with Relapsed and/or Refractory Solid Tumor Malignancies

Protocol No

LYELL-LYL-797-101

Phase

I

Summary

The purpose of this clinical study is to determine if the Study Drug LYL797, made up of your own immune cells that are genetically engineered, is safe at different doses and if it can kill specific tumor cells.

Description

Study to Assess the Safety of LYL797, ROR1-Targeting CAR T Cells, in Adults with R/R solid tumor

Participating Institutions

Froedtert Hospital

Status

OPEN TO ACCRUAL